Mallinckrodt reports Q3 adjusted EPS 49c, consensus 79c Reports Q3 revenue $570.0M, consensus $560.2M. The company said, "We are optimistic about Mallinckrodt’s pipeline, which will enable us to bring to market important new drugs, further driving growth within our Specialty Pharmaceuticals segment. At the same time, we are committed to becoming more profitable by driving operating efficiencies throughout the company. The restructuring program we are announcing today is part of that commitment.”
News For MNK From The Last 14 Days
Check below for free stories on MNK the last two weeks.